

AMENDMENTS TO THE CLAIMS

1. (currently amended) An isolated polypeptide, wherein the consisting of an amino acid sequence of said polypeptide consists of selected from the group consisting of:

(a) ~~an amino acid sequence shown in SEQ ID NO:2;~~

(b) ~~an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;~~

(c) ~~an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and~~

(d) ~~a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.~~

2 (currently amended) An isolated polypeptide, wherein the comprising an amino acid sequence of said polypeptide comprises selected from the group consisting of:

(a) ~~an amino acid sequence shown in SEQ ID NO:2;~~

(b) ~~an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;~~

(c) ~~an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and~~

(d) ~~a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.~~

3. (currently amended) An isolated antibody that selectively binds to a polypeptide of claim 2, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.
- 4-14. (canceled)
15. (new) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
16. (new) The antibody of claim 3, wherein the antibody is a monoclonal antibody.
17. (new) The antibody of claim 15, wherein the antibody is a monoclonal antibody.
18. (new) The antibody of claim 3, wherein the antibody is coupled to a detectable substance.
19. (new) The antibody of claim 15, wherein the antibody is coupled to a detectable substance.
20. (new) The antibody of claim 16, wherein the antibody is coupled to a detectable substance.
21. (new) The antibody of claim 17, wherein the antibody is coupled to a detectable substance.
22. (new) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

23. (new) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable carrier.
24. (new) A composition comprising the antibody of claim 16 and a pharmaceutically acceptable carrier.
25. (new) A composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.
26. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
 - b) an F(ab')₂ fragment; and
 - c) an Fv fragment.
27. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
 - b) an F(ab')₂ fragment; and
 - c) an Fv fragment.
28. (new) A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
29. (new) A composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier.